Tapentadol immediate release: a new treatment option for acute pain management

Figures & data

Figure 1 Chemical structure of tapentadol HCl.

Figure 2 Differences from placebo^a in mean SPID scores at 12, 24, 48, and 72 hours in patients with moderate to severe pain following bunionectomy treated with tapentadol IR 50 or 75 mg or oxycodone HCl IR 10 mg.⁵⁰

^aP < 0.001 vs placebo for all comparisons.

Abbreviations: SPID, sum of pain intensity difference; LS, least squares; CI, confidence interval; IR, immediate release.

Figure 3 Distribution of responder rates based on pain intensity at 48 hours in patients with postoperative pain following bunionectomy. Reproduced from Daniels et al (2009).⁵⁰ Copyright © 2009 Informa Healthcare.

Abbreviation: IR, immediate release.

Figure 4 Treatment-emergent adverse events occurring in ≥10% of patients in any treatment group among patients treated with placebo, tapentadol IR 50 or 75 mg, or oxycodone HCl IR 10 mg following bunionectomy.⁵⁰

Abbreviation: IR, immediate release.

Figure 5 The distribution of times to discontinuation due to adverse events from the 90-day safety study among patients with osteoarthritis hip or knee pain or low back pain treated with tapentadol IR or oxycodone IR. Reproduced from Hale et al (2009).⁵³

Abbreviation: IR, immediate release.

DanielsSCassonEStegmannJUA randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute painCurr Med Res Opin20092561551156119445652

 PubMed Web of Science ®Google Scholar

HaleMUpmalisDOkamotoALangeCRauschkolbCTolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind studyCurr Med Res Opin20092551095110419301989

 PubMed Web of Science ®Google Scholar